Oncology CRO | Charles River Discovery Research Services

Cachexia Model 

The Yoshida ascites hepatoma model induces cachexia and produces tissue wasting, particularly in skeletal muscle. This very aggressive, short-term model is used to evaluate the anti-cachectic effects of a therapy. With therapies typically beginning on the first day and continuing to the end of the study, heart, gastrocnemius and ascites are measured at sacrifice and used to evaluate efficacy of the therapy.

For more information about our cachexia model, please contact us at 1.877.CRIVER.1 or askcharlesriver@crl.com.

Discover the full range of Charles River Products and Services
The Source

For more information, contact us at:

1.877.CRIVER.1 (1.877.274.8371)
askcharlesriver@crl.com

view all

News & Events

view all
May 08 - Comparability Studies for Monoclon...
May 02 - Real Time Polymerase Chain Reactio...
May 20-May 22 - San Diego, CA - 2013 American Association of Pharmaceutical Scientists ...
May 23-May 23 - East Lansing, Michigan, USA - The Ins and Outs of Transgenic Colongy Ma...

Charles River Laboratories, Inc.